首页> 外国专利> Process for the therapeutic management of diarrhea predominant irritable bowel syndrome using Bacillus coagulans SBC-37-01, MTCC 5856

Process for the therapeutic management of diarrhea predominant irritable bowel syndrome using Bacillus coagulans SBC-37-01, MTCC 5856

机译：凝结芽孢杆菌 SBC-37-01，MTCC 5856对腹泻型肠易激综合征的治疗方法

展开▼

页面导航

摘要

著录项

相似文献

摘要

The present invention discloses a process for the therapeutic management of diarrhea predominant irritable bowel syndrome in humans comprising the oral administration of Bacillus coagulans SBC37-01, MTCC 5856 (containing not less than 2 billion spores) along with standard treatment of care in a specific manner. 展开▼

机译：本发明公开了一种用于治疗人类腹泻型肠易激综合症的方法，该方法包括口服凝结芽孢杆菌SBC37-01，MTCC 5856（含有不少于20亿个孢子）以及标准品。以特定方式对待护理。展开▼

著录项

公开/公告号US9579352B2

专利类型

公开/公告日2017-02-28

原文格式PDF

申请/专利权人 MUHAMMED MAJEED;KALYANAM NAGABHUSHANAM;NATARAJAN SANKARAN;PRITI VAIDYANATHAN;SIVAKUMAR ARUMUGAM;SURESH KUMAR KARRI;
展开▼

申请/专利号US201414536701

发明设计人 PRITI VAIDYANATHAN;NATARAJAN SANKARAN;MUHAMMED MAJEED;SURESH KUMAR KARRI;KALYANAM NAGABHUSHANAM;SIVAKUMAR ARUMUGAM;
展开▼

申请日2014-11-10

分类号A01N63/00;A61K35/742;A61K35/00;

国家 US

入库时间 2022-08-21 13:43:07

相似文献

专利

外文文献

中文文献

1. 使用凝结芽孢杆菌SBC37-01，MTCC 5856治疗性处理腹泻型肠易激综合征的方法 [P] . 中国专利： CN107206033B . 2021.04.27

2. 使用凝结芽孢杆菌SBC37‑01，MTCC 5856治疗性处理腹泻型肠易激综合征的方法 [P] . 中国专利： CN107206033A . 2017-09-26

3. Process for the therapeutic management of Diarrhea predominant irritable bowel syndrome using Bacillus coagulans SBC-37-01, MTCC 5856 [P] . 美国专利： US2016129054A1 . 2016-05-12

机译：使用凝结芽孢杆菌SBC-37-01，MTCC 5856来治疗腹泻型肠易激综合征的方法

4. SBC37-01 MTCC 5856 PROCESS FOR THE THERAPEUTIC MANAGEMENT OF DIARRHEA PREDOMINANT IRRITABLE BOWEL SYNDROME USING BACILLUS COAGULANS SBC37-01 MTCC 5856 [P] . 韩国专利： KR102157043B1 . 2020-09-17

机译： SBC37-01 MTCC 5856使用芽孢杆菌凝集素对腹泻优势肠易激综合征进行治疗管理的过程SBC37-01 MTCC 5856

5. SBC37-01 MTCC 5856 PROCESS FOR THE THERAPEUTIC MANAGEMENT OF DIARRHEA PREDOMINANT IRRITABLE BOWEL SYNDROME USING BACILLUS COAGULANS SBC37-01 MTCC 5856 [P] . 韩国专利： KR20170094254A . 2017-08-17

机译： SBC37-01 MTCC 5856使用芽孢杆菌凝集素对腹泻优势肠易激综合征进行治疗管理的过程SBC37-01 MTCC 5856

1. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study [J] . Muhammed Majeed, Kalyanam Nagabhushanam, Sankaran Natarajan, Nutrition Journal . 2015,第1期

2. Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. [J] . Dolin BJ Methods and findings in experimental and clinical pharmacology . 2009,第10期

3. The Therapeutic Effect of a Multistrain Probiotic on Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Study [J] . Seok-Hoon Lee, Nam-Seok Joo, Kwang-Min Kim, Gastroenterology research and practice . 2018,第1期

4. The Effects of Wumei Pill on Intestinal Flora and Neurotransmitters in Rats with Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) [C] . Xiaojie Ding, Xiling Sun, Xiaofei Yu, International Conference on Biotechnology and Bioengineering . 2019

5. Irritable Bowel Syndrome and Vitamin D Insufficiency: The Effects of Vitamin D Level on Irritable Bowel Syndrome [D] . Pollock, Mary E. 2018

6. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study [O] . Muhammed Majeed, Kalyanam Nagabhushanam, Sankaran Natarajan, 2016

7. Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: a randomised, double-blind, placebo controlled, multi-centre, pilot clinical study [O] . Muhammed Majeed, Kalyanam Nagabhushanam, Sivakumar Arumugam, 2018

1. Serotonin transporter and cholecystokinin in diarrhea-predominant irritable bowel syndrome: Associations with abdominal pain, visceral hypersensitivity and psychological performance [J] . Geng Qin ,Yu Zhang ,Shu-Kun Yao . 世界临床病例杂志 . 2020,第009期

2. Altered metabolism of bile acids correlates with clinical parameters and the gut microbiota in patients with diarrhea-predominant irritable bowel syndrome [J] . Wei Wei ,Hui-Fen Wang ,Yu Zhang . 世界胃肠病学杂志：英文版 . 2020,第45期

3. Altered profiles of fecal metabolites correlate with visceral hypersensitivity and may contribute to symptom severity of diarrhea-predominant irritable bowel syndrome [J] . Wen-Xue Zhang ,Yu Zhang ,Geng Qin . 世界胃肠病学杂志：英文版 . 2019,第43期

4. Increased intestinal mucosal leptin levels in patients with diarrhea-predominant irritable bowel syndrome [J] . De-Rong Liu ,Xiao-Juan Xu ,Shu-Kun Yao . 世界胃肠病学杂志：英文版 . 2018,第1期

5. Inhibitory effects of patchouli alcohol on stress-induced diarrhea-predominant irritable bowel syndrome [J] . Tian-Ran Zhou ,Jing-Jing Huang ,Zi-Tong Huang . 世界胃肠病学杂志：英文版 . 2018,第6期

6. 腹泻型肠易激综合征大鼠模型的建立及温肾健脾法干预腹泻型肠易激综合征大鼠的疗效评价 [C] . 苏晓兰 ,魏玮 ,史海霞 . 中华中医药学会脾胃病分会第二十五届全国脾胃病学术交流会 . 2013

7. 腹泻型肠易激综合征大鼠模型的建立及痛泻要方对肠易激综合征大鼠治疗作用的实验研究 [A] . 赵文娟 . 2008